Intellia Therapeutics, Inc. Form SC 13G/A February 08, 2019

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

SCHEDULE 13G

(Rule 13d-102)

Information Statement Pursuant to Rules 13d-1 and 13d-2 Under the Securities Exchange Act of 1934 (Amendment No. 2)*

INTELLIA THERAPUTICS, INC. (Name of Issuer)

Common Stock, \$0.0001 (Title of Class of Securities)

45826J105 (CUSIP Number)

December 31, 2018 (Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this schedule is filed:

Edgar Filing: Intellia Therapeutics, Inc. - Form SC 13G/A

[] Rule 13d-1(b)

[] Rule 13d-1(c)

[X] Rule 13d-1(d)

*The remainder of this cover page shall be filled out for a reporting person s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 (Act) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

Page 1 of 8 Pages

CUSIP No. 45826J105	13G	Page 2 of 8 Pages
1. NAME OF REPORTING	J PERSON	
S.S. OR I.R.S. IDENTIF	ICATION NO. OF ABOVE PERSON	
Atlag Vonture Fund IV	I D	
Atlas Venture Fund IX	, L.F.	
(a)		
2.		
CHECK THE APPROP	RIATE BOX IF A MEMBER OF A GROUP*	
(b)		
3. SEC USE ONLY		
4. CITIZENSHIP OR PLA	CE OF ORGANIZATION	
Delaware		
	5. SOLE VOTING POWER	
NUMBER OF		
SHARES BENEFICIALLY		
OWNED BY		

REPORTING6.SHARED VOTING POWERPERSON WITH

EACH

1,615,321

7. SOLE DISPOSITIVE POWER

8. SHARED DISPOSITIVE POWER

1,615,321

9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

1,615,321

10.

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES 0

11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

3.72%

12. TYPE OF REPORTING PERSON*

PN

1. NAME OF REPORTING PERSON

S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

Atlas Venture Associates IX, L.P.

(a) ...

2.

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

(b) ...

3. SEC USE ONLY

4. CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware

	5.	SOLE VOTING POWER
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH		
REPORTING PERSON WITH	6.	SHARED VOTING POWER
		1,615,321

7. SOLE DISPOSITIVE POWER

SHARED DISPOSITIVE POWER 1,615,321

9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

1,615,321

10.

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES 0

11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

3.72%

12. TYPE OF REPORTING PERSON*

PN

1

1,615,321

PERSON WITH

7. SOLE DISPOSITIVE POWER

8. SHARED DISPOSITIVE POWER

1,615,321

9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

1,615,321

10.

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES 0

11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

3.72%

12. TYPE OF REPORTING PERSON*

00

CUSIP No. 45826J105	;	SCHEDULE 13G		Page 5 of 8 Pages
Item 1(a). Na	ame of Issue	r		
The name of the issuer to) which this fi	ling on Schedule 13G/A relates is Intellia Theraper	utics, Inc. (the <u>Cor</u>	mpany).
Item 1(b). Ad	ldress of Issu	er s Principal Executive Offices		
The principal executive of	offices of the	Company are located at 40 Erie Street, Suite 130, C	Cambridge, Massach	nusetts 02139.
Item 2(a). Na	ame of Perso	n Filing		
This Statement is being f general partner of Atlas I	iled on behal X, and Atlas	f of Atlas Venture Fund IX, L.P. (" <u>Atlas IX</u> "), Atla Venture Associates IX, LLC (" <u>AVA IX LLC</u> "), th	s Venture Associate e sole general partne	es IX, L.P. (" <u>AVA IX LP</u> "), the sole er of AVA IX LP.
Item 2(b). Ad	ldress of Prin	ncipal Business Office or, if none, Residence		
The principal business ad	ldress of each	of Atlas IX, AVA IX LP, and AVA IX LLC is 46	Wareham Street, Bo	oston MA, 02118.
Item 2(c). Ci	itizenship			
Each of Atlas IX, AVA I	X LP and AV	A IX LLC is organized under the laws of Delawar	е.	
Item 2(d). Tit	tle of Class o	f Securities		

The class of equity securities of the Company to which this filing on Schedule 13G/A relates is Common Stock, par value \$0.0001 (<u>Common Stock</u>).

Edgar Filing: Intellia Therapeutics, Inc. - Form SC 13G/A

Item 2(e). CUSIP Number

The CUSIP number of the Company s Common Stock is 45826J105.

Item 3. applicable.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: Not
(a)	[] Broker or dealer registered under section 15 of the Act (15 U.S.C. 780).
(b)	[] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 73c).
(c)	[] Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
(d)	[] Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
(e)	[] An investment adviser in accordance with §13d-1(b)(1)(ii)(E).
(f)	[] An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F).
(g)	[] A parent holding company or control person in accordance with $240.13d-1(b)(1)(ii)(G)$.
(h)	[] A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813).
(i) Company Ad	[] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment et of 1940 (15 U.S.C. 80a-3).
(j)	[] Group, in accordance with §240.13d-1(b)(1)(ii)(J).

[] If this statement is filed pursuant to §240.13d-1(c), check this box.

CUSIP No. 45826J105	SCHEDULE 13G	Page 6 of 8 Pages

Item 4.

Ownership

Item 4(a). Amount beneficially owned

As of the close of business on December 31, 2018, Atlas IX is the record holder of 1,615,321 shares of Common Stock (the "Atlas Shares"). AVA IX LP is the sole general partner of Atlas IX. AVA IX LLC is the sole general partner of AVA IX LP. No person other than the respective owner referred to herein of the Atlas Shares is known to have the right to receive or the power to direct the receipt of dividends from or the proceeds from the sale of such Atlas Shares. Each of Atlas IX, AVA IX LP, and AVA IX LLC disclaim beneficial ownership of the Atlas Shares except for such shares, if any, such person holds of record.

Item 4(b). Percent of Class

As of the close of business on December 31, 2018, Atlas IX was the beneficial owner of 3.72% of the Common Stock, based on 43,419,303 shares outstanding as listed in the Company s 10-Q filed on October 31, 2018.

Item 4(c). Number of shares as to which the person has:

		Number of Shares	of Common Stock	
Reporting Person	(i)	(ii)	(iii)	(iv)
Atlas IX	-0-	1,615,321	-0-	1,615,321
AVA IX LP	-0-	1,615,321	-0-	1,615,321
AVA IX LLC	-0-	1,615,321	-0-	1,615,321

(i) Sole power to vote or direct the vote

- (ii) Shared power to vote or to direct the vote
- (iii) Sole power to dispose or to direct the disposition of
- (iv) Shared power to dispose or to direct the disposition of

Item 5. Ownership of Five Percent or Less of a Class

Each Filing Person has ceased to own beneficially more than 5% of the outstanding Common Stock of the Company.

Edgar Filing: Intellia Therapeutics, Inc. - Form SC 13G/A Item 6. Ownership of More than Five Percent on Behalf of Another Person Not Applicable. Item 7. Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding **Company**: Not Applicable. Identification and Classification of Members of the Group Item 8. Not Applicable. The Filing Persons expressly disclaim membership in a "group" as used in Rule 13d-5(b)(1). Item 9. Notice of Dissolution of Group Not Applicable. Item 10. Certification Not Applicable. This statement on Schedule 13G is not filed pursuant to Rule 13d-1(b) or 13(d)-1(c).

CUSIP No. 45826J105	SCHEDULE 13G	Page 7 of 8 Pages

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: February 8, 2018

ATLAS VENTURE FUND IX, L.P.

By: Atlas Venture Associates IX, L.P., its general partner By: Atlas Venture Associates IX, LLC, its general partner

By:

/s/ Frank Castellucci Name: Frank Castellucci Title: Secretary

ATLAS VENTURE ASSOCIATES IX, L.P. By: Atlas Venture Associates IX, LLC, its general partner

By:

/s/ Frank Castellucci Name: Frank Castellucci Title: Secretary

ATLAS VENTURE ASSOCIATES IX, LLC

By:

/s/ Frank Castellucci Name: Frank Castellucci Title: Secretary

CUSIP No. 45826J105	SCHEDULE 13G	Page 8 of 8 Pages

Exhibit A

Joint Filing Agreement

The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him, her or it contained herein, but shall not be responsible for the completeness and accuracy of the information concerning the other entities or persons, except to the extent that he, she or it knows or has reason to believe that such information is inaccurate.

Dated: February 8, 2018

ATLAS VENTURE FUND IX, L.P.

By: Atlas Venture Associates IX, L.P., its general partner By: Atlas Venture Associates IX, LLC, its general partner

By:

/s/ Frank Castellucci Name: Frank Castellucci Title: Secretary

ATLAS VENTURE ASSOCIATES IX, L.P. By: Atlas Venture Associates IX, LLC,

its general partner

By:

/s/ Frank Castellucci Name: Frank Castellucci Title: Secretary

ATLAS VENTURE ASSOCIATES IX, LLC

By:

/s/ Frank Castellucci Name: Frank Castellucci Title: Secretary